Renalytix AI plc - Asset Resilience Ratio

Latest as of December 2024: 3.64%

Renalytix AI plc (RENX) has an Asset Resilience Ratio of 3.64% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Renalytix AI plc strategic asset allocation index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

GBX417.00K
≈ $50.74 USD Cash + Short-term Investments

Total Assets

GBX11.44 Million
≈ $1.39K USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2012–2025)

This chart shows how Renalytix AI plc's Asset Resilience Ratio has changed over time. See RENX net asset quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Renalytix AI plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see RENX market cap overview.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents GBX0.00 0%
Short-term Investments GBX417.00K 3.64%
Total Liquid Assets GBX417.00K 3.64%

Asset Resilience Insights

  • Limited Liquidity: Renalytix AI plc maintains only 3.64% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Renalytix AI plc Industry Peers by Asset Resilience Ratio

Compare Renalytix AI plc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
INVENTURUS KNOWLEDGE SO L
NSE:IKS
Health Information Services 0.39%
Waystar Holding Corp. Common Stock
NASDAQ:WAY
Health Information Services 2.13%
DocCheck AG
XETRA:AJ91
Health Information Services 7.30%
Pro Medicus Ltd
AU:PME
Health Information Services 54.64%
Echoiq Ltd
AU:EIQ
Health Information Services 11.12%
ARTRYA Ltd
AU:AYA
Health Information Services 32.70%
Cogstate Ltd
AU:CGS
Health Information Services 54.90%
Oneview Healthcare Plc
AU:ONE
Health Information Services 29.71%

Annual Asset Resilience Ratio for Renalytix AI plc (2012–2025)

The table below shows the annual Asset Resilience Ratio data for Renalytix AI plc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 1.64% GBX100.00K
≈ $12.17
GBX6.10 Million
≈ $742.19
-7.14pp
2024-06-30 8.78% GBX700.00K
≈ $85.17
GBX7.97 Million
≈ $969.96
+7.30pp
2023-12-31 1.48% GBX1.11 Billion
≈ $135.30K
GBX75.27 Billion
≈ $9.16 Million
-1.99pp
2023-06-30 3.47% GBX1.46 Million
≈ $177.64
GBX42.12 Million
≈ $5.12K
-0.87pp
2022-06-30 4.34% GBX2.74 Million
≈ $333.87
GBX63.26 Million
≈ $7.70K
-4.72pp
2021-06-30 9.06% GBX9.29 Million
≈ $1.13K
GBX102.58 Million
≈ $12.48K
+6.68pp
2020-06-30 2.38% GBX982.00K
≈ $119.48
GBX41.30 Million
≈ $5.02K
-1.06pp
2019-06-30 3.44% GBX994.00K
≈ $120.94
GBX28.92 Million
≈ $3.52K
+2.44pp
2016-12-31 1.00% GBX594.67 Million
≈ $72.35K
GBX59.39 Billion
≈ $7.23 Million
-0.14pp
2015-12-31 1.14% GBX647.30 Million
≈ $78.76K
GBX56.80 Billion
≈ $6.91 Million
-0.11pp
2014-12-31 1.25% GBX725.05 Million
≈ $88.22K
GBX58.13 Billion
≈ $7.07 Million
-0.80pp
2013-12-31 2.05% GBX1.29 Billion
≈ $156.50K
GBX62.68 Billion
≈ $7.63 Million
+0.51pp
2012-12-31 1.54% GBX937.44 Million
≈ $114.06K
GBX60.90 Billion
≈ $7.41 Million
--
pp = percentage points

About Renalytix AI plc

LSE:RENX UK Health Information Services
Market Cap
$101.03K
GBX830.34 Million GBX
Market Cap Rank
#31287 Global
#1122 in UK
Share Price
GBX1.90
Change (1 day)
+0.00%
52-Week Range
GBX1.80 - GBX10.75
All Time High
GBX1220.00
About

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from … Read more